Sanofi: FDA Approves Fluzone High-Dose Quadrivalent for Adults 65 and Older
04 Noviembre 2019 - 05:14PM
Noticias Dow Jones
By Stephen Nakrosis
Sanofi on Monday said the U.S. Food and Drug Administration
approved a supplemental Biologics License Application for its
Fluzone influenza vaccine for use by adults 65 and older.
The application was for the company's Fluzone High-Dose
Quadrivalent (Influenza Vaccine), Sanofi said.
"Fluzone High-Dose Quadrivalent is given to people 65 years of
age and older to help prevent influenza disease caused by influenza
A and B strains contained in the vaccine," the company said.
David Loew, Sanofi Executive Vice President and head of Sanofi
Pasteur, said, "We are excited to build upon the success of
trivalent Fluzone High-Dose with this FDA approval to expand
protection for an additional B strain. We have submitted filings
with additional regulatory bodies outside the U.S. and anticipate
approval in the European Union next spring."
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 04, 2019 17:59 ET (22:59 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024